Zanubrutinib Plus Obinutuzumab Vs Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study

Wojciech Jurczak,[1] Pier Luigi Zinzani,[2] Jiří Mayer,[3] Fontanet Bijou,[4] Ana C. de Oliveira,[5] Roderick Johnson,[6] Marek Trněný,[7] Pil Kim,[8] Richard Delarue,[9] Judith Trotman[10]

[1]MSC National Research Institute of Oncology, Krakow, Poland; [2]Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy; [3]Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; [4]Bergonie Institute, Bordeaux, France; [5]Catalan Institute of Oncology (ICO) Duran i Reynals Hospital, Barcelona, Spain; [6]St. James's University Hospital Trust, Leeds, UK; [7]General University Hospital in Prague, Prague, Czech Republic; [8]BeiGene (Shanghai) Co., Ltd., Shanghai, China and BeiGene USA, Inc., San Mateo, CA, USA; [9]Beigene Switzerland, GmbH, Basel, Switzerland; [10]Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia

Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Prof. Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

Data originally presented at the 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023; Chicago, IL, USA. Abstract 7545.

Speaker Disclosures

Wojciech Jurczak had a consulting role with AbbVie, AstraZeneca, BeiGene, Lilly, Pfizer, Roche, Swedish Orphan Biovitrum, Takeda; and received research funding from AbbVie, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Janssen, Lilly, Merck, Pfizer, Roche, Swedish Orphan Biovitrum, Takeda.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

Background

- In a phase 1b/2 study that included patients with R/R FL, the combination of zanubrutinib[a] + obinutuzumab was generally well tolerated, with an ORR of 72% and a complete response rate of 39%[1]
- The ROSEWOOD trial (BGB-3111-212; NCT03332017) examined zanubrutinib + obinutuzumab vs obinutuzumab in patients with R/R FL who received ≥2 prior lines of therapy
- At the primary analysis, the trial met its primary endpoint of ORR[2]
  - Zanubrutinib + obinutuzumab, 68.3%
  - Obinutuzumab, 45.8%

} *P*=.0017

Here we report an updated analysis of the ROSEWOOD trial with a median follow-up of 20.2 months

FL, follicular lymphoma; ORR, objective response rate; R/R, relapsed or refractory.

[a] Zanubrutinib monotherapy is approved in the US and EU for the treatment of adult patients with chronic lymphocytic leukemia; marginal zone lymphoma after ≥1 prior anti-CD20–based therapy; Waldenström macroglobulinemia (in EU: after ≥1 prior therapy, or as first-line treatment if unsuitable for chemoimmunotherapy); and mantle cell lymphoma after ≥1 prior therapy (US only).

1. Tam CS, et al. *Blood Adv*. 2020;4(19):4802-4811; 2. Zinzani PL, et al. ASCO 2022. Abstract 7510.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

ROSEWOOD study design



127 sites; 17 countries/regions
Randomized November 2017 to June 2021

AE, adverse event; BTK, Bruton tyrosine kinase; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; IRC, independent review committee; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; R/R, relapsed or refractory; TTNT, time to next treatment.

[a] Zanubrutinib was given orally at 160 mg twice daily. [b] Obinutuzumab was given intravenously at 1000 mg in both arms on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6, and then every 8 weeks up to a maximum of 20 doses. [c] Secondary endpoint.

1. Cheson BD, et al. *J Clin Oncol*. 2014;32(27):3059-3068.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

One-third of patients were still receiving zanubrutinib + obinutuzumab at the time of this updated analysis



Median follow-up, 20.2 months

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study. Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

The study population was heavily pretreated and had refractory disease

Characteristics	Zanubrutinib + obinutuzumab (n=145)	Obinutuzumab (n=72)
Age, median (range), years	63.0 (31-84)	65.5 (32-88)
ECOG PS of ≥1, n (%)	59 (40.6)	41 (57.0)
FLIPI score of ≥3, n (%)	77 (53.1)	37 (51.4)
Ann Arbor stage III-IV, n (%)	119 (82.1)	60 (83.3)
Bulky disease (≥7 cm), n (%)	23 (15.9)	12 (16.7)
High LDH level (>ULN), n (%)	49 (33.8)	29 (40.3)
High tumor burden per GELF criteria, n (%)	83 (57.2)	40 (55.6)
No. of prior lines of therapy, median (range)	3 (2-11)	3 (2-9)
Refractory to rituximab, n (%)	78 (53.8)	36 (50.0)
Refractory to most recent line of therapy, n (%)	47 (32.4)	29 (40.3)
PD ≤24 months after starting first line of therapy, n (%)	50 (34.5)	30 (41.7)
Prior therapy, n (%)		
Chemoimmunotherapy	143 (98.6)	71 (98.6)
Anthracyclines	118 (81.4)	57 (79.2)
Cyclophosphamide	136 (93.8)	68 (94.4)
Bendamustine	79 (54.5)	40 (55.6)

ECOG PS, Eastern Cooperative Oncology Group performance status; FLIPI, Follicular Lymphoma International Prognostic Index; GELF, Groupe d'Etude des Lymphomes Folliculaires; LDH, lactate dehydrogenase; PD, progressive disease; ULN, upper limit of normal.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

Median treatment exposure for zanubrutinib + obinutuzumab was twice that for obinutuzumab alone

Zanubrutinib + obinutuzumab

- Median zanubrutinib exposure was 12.2 months (range, 0.5-44.1 months)
  - 56.7% of patients received ≥12 cycles
  - Median relative dose intensity was 98.9% (range, 30.7%-100%)
  - Median number of obinutuzumab infusions was 11 (range, 3-20)

Obinutuzumab

- Median exposure was 6.5 months (range, 0.1-28.7 months)
  - Median number of infusions was 9 (range, 3-20)

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

ORR difference by IRC was 22.7% in favor of zanubrutinib + obinutuzumab at the median study follow-up of 20.2 months

Endpoint	Zanubrutinib + obinutuzumab (n=145)	Obinutuzumab (n=72)	2-sided *P* value
ORR by IRC[a] (95% CI), %	69.0 (60.8-76.4)	45.8 (34.0-58.0)	.0012
CR	39.3	19.4	.0035
PR	29.7	26.4	–
DOR by IRC			
Median (95% CI), months	NE (25.3-NE)	14.0 (9.2-25.1)	–
18-month DOR rate (95% CI), %	69.3 (57.8-78.2)	41.9 (22.6-60.1)	–
DOCR by IRC			
Median (95% CI), months	NE (26.5-NE)	26.5 (2.7-NE)	–
18-month DOCR rate (95% CI), %	87.4 (73.8-94.2)	51.1 (21.0-74.9)	–

CR, complete response; DOCR, duration of CR; DOR, duration of response; IRC, independent review committee; NE, not estimable; ORR, objective response rate; PR, partial response.
[a] ORR difference by IRC was 22.7%; 95% CI, 9.0%-36.5%.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

Zanubrutinib + obinutuzumab showed consistent benefit over obinutuzumab across prespecified subgroups

Subgroups	Response/patients		Risk difference (95% CI), %
	Obinutuzumab	Zanubrutinib + obinutuzumab	
All patients in ITT	33/72	100/145	22.7 (9.0-36.5)
Age, years			
<65	14/32	58/83	26.1 (6.3-45.9)
≥65	19/40	42/62	20.2 (0.9-39.6)
<75	30/60	89/130	18.5 (3.5-33.4)
≥75	3/12	11/15	48.3 (15.2-81.5)
No. of prior lines of therapy			
2-3	27/54	77/108	21.3 (5.5-37.1)
>3	6/18	23/37	28.8 (2.0-55.6)
Bulky disease: any target lesion longest diameter ≥7 cm			
Yes	3/12	11/23	22.8 (−9.1 to 54.7)
No	30/60	89/122	23.0 (8.0-37.9)
FLIPI risk category			
Low (0-1)	3/9	21/29	39.1 (4.3-73.9)
Intermediate (2)	13/24	26/34	22.3 (−2.2 to 46.8)
High (≥3)	17/37	49/77	17.7 (−1.6 to 37.0)
Rituximab-refractory status			
Refractory	14/36	47/78	21.4 (2.1-40.6)
Not refractory	19/36	53/67	26.3 (7.3-45.3)
Refractory status to most recent line of therapy			
Refractory	11/29	29/47	23.8 (1.3-46.2)
Not refractory	21/42	66/93	21.0 (3.3-38.7)
Progression of disease ≥6 months of completion of the most recent line of therapy			
Yes	12/39	42/71	28.4 (9.9-46.8)
No	19/30	53/67	15.8 (−4.0 to 35.6)
Progression of disease ≥24 months of starting the first line of chemoimmunotherapy			
Yes	9/22	25/39	23.2 (−2.3 to 48.7)
No	14/31	40/59	22.6 (1.4-43.8)



FLIPI, Follicular Lymphoma International Prognostic Index; ITT, intent to treat.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study. Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

DOR and PFS were longer with zanubrutinib + obinutuzumab

DOR by IRC



No. at risk																					
Zanubrutinib + obinutuzumab	100	97	82	73	68	59	51	43	40	33	23	21	19	12	10	7	3	3	2	1	1	0
Obinutuzumab	33	29	24	23	20	16	13	11	10	9	8	6	5	3	2	2	2	0				

PFS by IRC



No. at risk																					
Zanubrutinib + obinutuzumab	145	135	116	96	92	79	67	62	56	45	38	35	25	22	15	10	9	5	3	3	1	1	0
Obinutuzumab	72	63	42	34	30	27	19	16	15	12	11	9	8	8	5	3	3	2	1	1	0		

HR, hazard ratio; IRC, independent review committee; mDOR, median duration of response; mPFS, median progression-free survival; NE, not estimable.
[a] Descriptive 2-sided *P* value.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

TTNT and OS were prolonged with zanubrutinib + obinutuzumab

TTNT



No. at risk

Zanubrutinib + obinutuzumab	145	137	125	118	107	98	91	80	71	62	53	47	44	40	29	22	17	12	10	6	3	3	3	0
Obinutuzumab	72	65	49	44	41	32	30	24	20	18	16	13	11	9	8	5	4	2	1	1	0			

OS



No. at risk

	145	139	133	129	123	119	113	102	92	81	70	62	56	51	41	33	26	20	17	11	4	4	3	0
	72	67	63	62	57	54	49	48	43	39	36	32	25	23	18	14	13	8	5	3	1	1	1	0

HR, hazard ratio; mOS, median overall survival; mTTNT, median time to next treatment; NE, not estimable.
[a] Descriptive 2-sided *P* value.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

There were no unexpected safety findings with zanubrutinib + obinutuzumab

Common nonhematologic TEAEs (any grade)



Grade ≥3 nonhematologic TEAEs

n (%)	Zanubrutinib + obinutuzumab (n=143)	Obinutuzumab (n=71)
Pneumonia	14 (9.8)	3 (4.2)
COVID-19	8 (5.6)	2 (2.8)
COVID-19 pneumonia	5 (3.5)	2 (2.8)
Diarrhea	4 (2.8)	1 (1.4)
Febrile neutropenia	3 (2.1)	1 (1.4)
Atrial fibrillation	2 (1.4)	0
IRR	1 (0.7)	3 (4.2)
Hypertension	1 (0.7)	1 (1.4)

IRR, infusion-related reaction; TEAE, treatment-emergent adverse event.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study. Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

EAIRs for TEAEs of special interest were similar in both arms, except for any grade hemorrhage

EAIRs for TEAEs of special interest



EAIR, exposure-adjusted incidence rate; TEAE, treatment-emergent adverse event.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study. Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

Conclusions

- In the ROSEWOOD study, zanubrutinib + obinutuzumab demonstrated meaningful efficacy and a manageable safety profile in heavily pretreated patients with R/R FL
- This longer follow-up analysis provides evidence of the significant complete response rate, with longer PFS and TTNT, with zanubrutinib + obinutuzumab vs obinutuzumab alone
  - A consistent benefit was observed across key prespecified subgroups
- Zanubrutinib + obinutuzumab demonstrated a favorable risk-benefit profile and may represent a potential novel combination therapy for patients with R/R FL
- A phase 3 study of zanubrutinib + obinutuzumab in patients who previously received ≥1 line of systemic therapy is now underway (MAHOGANY; NCT05100862)

FL, follicular lymphoma; PFS, progression-free survival; R/R, relapsed or refractory; TTNT, time to next treatment.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.
Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl

Acknowledgments

- The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating centers
- This study was sponsored by BeiGene, Ltd.
- Medical writing support was provided by Nicole Lopez, PhD of Articulate Science, LLC, and was funded by BeiGene, Ltd.

Jurczak W, et al. Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Presented at: 31st Congress of the Polish Society of Hematology and Transfusion Medicine; September 14-16, 2023; Katowice, Poland.

Correspondence: Wojciech Jurczak, MD, PhD; wojciech.jurczak@lymphoma.edu.pl